By Connor Hart
Shares of Theratechnologies jumped after the company received Food and Drug Administration approval for Egrifta WR, its treatment for excess abdominal fat in adults with HIV and lipodystrophy.
The stock climbed 50%, to $2.32, in after-hours trading Tuesday. Shares are up 15% in the past year through the close, despite having fallen 16% in the past three months.
The Canadian biopharmaceutical company said the treatment is set to replace Egrifta SV. The new formulation is a daily injectable requiring weekly reconstitution, meaning it requires less than half the administration volume as the current formulation, which is reconstituted daily.
The treatment will be manufactured at a new U.S.-based contract drug manufacturing organization, and is set to be patent protected in the U.S. until 2033, the company said.
"We are pleased to offer this improved, more convenient version of tesamorelin for injection to help people with HIV and their healthcare providers more effectively manage comorbidities like lipodystrophy, which today often presents as central adiposity," Chief Medical Officer Christian Marsolais said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 25, 2025 18:16 ET (22:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。